Yancey Warren, Jr, MD, MAT, and Lejla Hadzikadic-Gusic, MD, MSc, spoke with CancerNetwork® about their work investigating the use of integrative oncology services among young patients diagnosed with breast cancer.
The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Panelists discuss how to monitor and manage adverse effects, particularly chimeric antigen receptor (CAR) T cell–specific reactions, in patients receiving this therapy and how to collaborate with the CAR T-cell therapy team during the treatment phase, emphasizing the most critical aspects of patient care at this stage.
Zhubin J. Gahvari, MD, MS, and Natalie S. Callander, MD, provide a comprehensive overview of current treatment paradigms in relapsed and refractory multiple myeloma.
Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.
This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.
Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.
Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.
Investigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
Looking toward the future management of metastatic HSPC, experts consider the results of triplet combination trials like ARASENS and PEACE-1.
Hans Kristian Nugraha, MD, SpOT, and colleagues detail the potential benefits of an arthroscopic surgical approach through a case study of a patient with giant cell tumor of bone.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.
Dr Cesar Perez reacts to the utilization of next-generation sequencing in head and neck squamous cell carcinoma and highlights future areas of study.
Javier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.
Panelists discuss how to manage talquetamab-associated adverse events, such as skin toxicities and dysgeusia, sharing their clinical experience with toxicity timing, frequency, and key strategies for fellow oncologists implementing bispecific antibodies in relapsed/refractory multiple myeloma.
Focal therapy for prostate cancer could balance undertreatment and overtreatment of localized prostate cancer for highly selected patients. Long-term oncologic outcomes are not yet available for any modality. Patients should be informed regarding currently available outcomes, the necessity of adherence to a stringent follow-up protocol, and the possible need for additional targeted therapy or future radical treatment in case of recurrence.
Sunvozertinib shows a similar safety profile to other EGFR tyrosine kinase inhibitors in the treatment of EGFR wild-type non–small cell lung cancer in the WO-KONH6 study.